5 Key Takeaways

• 1

  The 4CMenB vaccine was associated with 38.4% effectiveness against gonorrhea among adolescents in a high-prevalence setting.

• 2

  The study involved 30,650 adolescents, with 9.6% fully vaccinated and 42.4% identifying as Aboriginal or Torres Strait Islander.

• 3

  Meningococcal carriage increased from 4% to 6.2%, driven by genogroup B and nongroupable strains, while disease-associated carriage remained stable.

• 4

  Limitations included lower-than-expected vaccine uptake and missing data, impacting the robustness of the findings.

• 5

  4CMenB should complement, not replace, existing gonorrhea prevention strategies, and further randomized studies are needed to explore its efficacy.